Publication date: Mar 22, 2025
Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti-PD1 therapy. From the prospective multicentre real-world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 +/- 4 weeks; n = 229) and no disease recurrence during therapy (A) and patients with a premature end of treatment (
| Concepts | Keywords |
|---|---|
| 524weeks | Adjuvant |
| Free | Anti |
| Immunotherapy | Clinical |
| Stage | Duration |
| Early | |
| Immunotherapy | |
| Melanoma | |
| Outcome | |
| Pd1 | |
| Recurrence | |
| Resected | |
| Survival | |
| Termination | |
| Therapy | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | recurrence |
| disease | MESH | skin cancer |
| drug | DRUGBANK | Nivolumab |
| drug | DRUGBANK | Pembrolizumab |